The theoretical risk of diagnosing or developing C-cell hyperplasia or MTC may warrant future investigation into the cost-effectiveness of screening patients with calcitonin prior to starting GLP-1 agonist treatment outside of clinical trials. This evidence concerns the gene CALCA and C-cell hyperplasia.